Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Pacific Biosciences of California, Inc.

PACB

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Last trade $1.81
Day change -$0.035 (-1.90%)
Day range $1.74 – $1.91
Volume 6,661,124
Market cap $575M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$574.52M
Price / earnings
—
Price / book
-9.36×
Price / sales
3.56×
EV / sales
7.2×
EV / EBITDA
-7.92×

Profitability

Earnings per share
-$0.42
Return on assets
-18.2%
Return on equity
213.8%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-10.48×
Current ratio
4.62×
Quick ratio
3.72×
Cash ratio
0.84×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$143.4M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PACB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$40.56M$39.01M$37.18M$44.65M$38.44M$39.77M$37.15M$39.22M
Cost of revenue$27.09M$26.37M$24.34M$28.08M$22.54M$25.08M$38.52M$29.17M
Gross profit$13.47M$12.64M$12.84M$16.57M$15.9M$14.68M-$1.37M$10.06M
Selling, general and administrative$29.42M$33.39M$31.15M$34.05M$31.1M$36.18M$40.17M$41.64M
Research and development$20.22M$23.02M$19.61M$22.88M$22.85M$22.53M$29.05M$27.47M
Total operating expenses$50.47M$57.25M$66.99M$57.76M$54.78M$59.54M$446.26M$163.09M
Operating income-$37M-$44.61M-$54.15M-$41.2M-$38.88M-$44.85M-$447.63M-$153.03M
Interest expense-$2.06M-$2.11M-$1.74M-$1.74M-$1.74M-$1.74M-$1.74M-$2.76M
Income before taxes-$37.58M-$44.68M-$8.09M-$40.17M-$37.62M-$41.9M-$426.38M$2.69M
Income taxes$269K$58K$184K$202K$383K$35K-$302K$316K
Net income-$37.85M-$44.74M-$8.28M-$40.37M-$38M-$41.93M-$426.08M$2.37M
Net income attributable to common shareholders-$37.85M-$44.74M-$8.28M-$40.37M-$38M-$41.93M-$426.08M$2.37M
EBITDA-$33.01M-$40.75M-$35.53M-$37.44M-$35.4M-$41.18M-$61.11M-$52.03M
Basic earnings per share-$0.12-$0.14-$0.03-$0.13-$0.13-$0.14-$1.44$0.01
Diluted earnings per share-$0.12-$0.14-$0.03-$0.13-$0.13-$0.14-$1.44$0.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's Why Pacific Biosciences (PACB) Is a Great 'Buy the Bottom' Stock Now

Pacific Biosciences (PACB) has declined 13.1% over the past week but shows technical signs of a potential trend reversal with a hammer chart pattern formation. Fundamental support comes from rising analyst earnings estimate revisions (up 1.9% over 30 days) and a Zacks Rank #2 (Buy) rating, positioning the stock in the top 20% of covered stocks.

Zacks Investment Research

Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts

Pacific Biosciences of California (PACB) stock rose 2.47% to $2.90 on October 29, 2026, outperforming a declining broader market. The genetic analysis technology company has gained 19.41% over the past month. However, the company faces headwinds with forecasted Q3 EPS of -$0.13 (down 8.33% YoY) and revenue of $37.86 million (down 1.52% YoY). PACB carries a Zacks Rank #3 (Hold) rating, and its Medical-Instruments industry ranks in the bottom 40% of all industries.

Zacks Investment Research

Glaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates

Glaukos (GKOS) reported quarterly earnings of $0.47 per share, significantly beating the consensus estimate of a loss of $0.12 per share, with a 491.67% earnings surprise. The company posted revenues of $211.03 million, surpassing estimates by 24.99% and up 58% year-over-year. The stock has gained 60.5% year-to-date and holds a Zacks Rank #2 (Buy) rating, though the Medical-Instruments industry ranks in the bottom 40% of Zacks industries.

GlobeNewswire Inc.

Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity

Thailand's NGS market is projected to reach $305.21 million by 2036, growing at a 12.7% CAGR from $92.03 million in 2026. Growth is driven by the Genomics Thailand national precision medicine initiative, rising clinical adoption in oncology and rare diseases, expanded reimbursement under the Universal Coverage Scheme, and increasing demand for outsourced sequencing services. Commercial sequencing services and clinical applications in oncology are expected to be the fastest-growing segments.

Zacks Investment Research

Here's Why You Should Hold PacBio Stock in Your Portfolio for Now

Pacific Biosciences (PacBio) reported mixed Q2 2026 results with strong clinical adoption and consumables growth, but cut its full-year revenue guidance to $155-165M and delayed cash flow breakeven to 2028. While clinical shipments jumped 67% and EMEA revenues surged 52%, instrument sales fell 9% and Asia-Pacific revenues declined 45% due to funding constraints and slower SPRQ-Nx adoption.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.